圣诺医药-B2024年度报告

目錄 公司資料2主席報告4五年財務概要6管理層討論與分析7董事及高級管理人員27董事會報告33企業管治報告69獨立核數師報告106綜合損益及其他全面收益表110綜合財務狀況表111綜合權益變動表113綜合現金流量表115綜合財務報表附註117釋義204技術詞彙表210 公司資料 2024102120241021 20241015 20241021 David Mark Evans2024620 2024628202525202521720252520246282025112024620 20245102024620 2024115202525202511 2025252024113020252520241130 20252172025112024620 2024113020241130 2025217202462820252192025112025112024620 Sirnaomics, Inc.20511 Seneca Meadows Parkway Suite 200GermantownMD 20876U.S. 公司資料 99 218A4415 1 18346 Wells Fargo Bank, N.A.420 Montgomery StreetSan FranciscoCA 94104U.S. PO Box 309, Ugland HouseGrand Cayman, KY1–1104Cayman Islands 16–2011 Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary HallCricket SquareGrand Cayman, KY1–1102Cayman Islands 66101001 183171712–1716 Maples and Calder (Hong Kong) LLP1826 38223 www.sirnaomics.com 2257 SirnaomicsSirnaomics20241231 2024STP705STP705isSCCIIISTP705IRNAi STP707IsiRNA GalAhead™STP122G ISTP125GINDGalAhead™PNPmuRNA™ 主席報告 202420252025PNPGalAhead SirnaomicsRNA Sirnaomics 管理層討論與分析 Sirnaomics2007RNASirnaomics— PNPGalAhead™ STP705STP707STP705STP707PNP (NMSC)STP705STP7052023FDAIIFDASTP705II/IIIIIIFDASTP705 STP707STP707FDA1150STP707(SD)T(TME)SDSTP707 STP705STP707RNAi STP705isSCCsiRNAIFDAII 管理層討論與分析 GalAhead™ GalNAcGalAhead™mxRNAmuRNA STP122GGalAhead™ mxRNASTP122GFDAISTP122G2025 GalAhead™GalAhead™STP122GGalAhead™ muRNARNA RNAi SirnaomicssiRNARNA RNAGMPsiRNA SirnaomicsRNA 管理層討論與分析 2025 SirnaomicsRNANMSCSTP705IIISTP707ISTP122GSTP125GSTP144GSirnaomicsPNPGalAhead™(AODC)RNA isSCC =BCC =PNP=(PNP) RNAiPNP-IT =PNPPNP-Subcu =PNPPNP-ID =PNPPNP-IV =PNPGalAhead™ =GalNAcRNAiGalNAc RNAimxRNA-= mxRNA™RNAimuRNA-= muRNA™RNAi 管理層討論與分析 RNAimmuneSirnaomicsmRNASirnaomicsSTP705STP707STP122GsiRNARNAimmuneRV-1730RV-1770mRNASirnaomicssiRNARNAimmune STP705NMSC isSCCBCCSTP705β-1TGF-β1-2COX-2isSCCIIaIIbSTP705FDAII/IIIBCC II(AE)(SAE) STP705I(LSR)II STP707 STP707TGF-β1COX-250ISTP707STP707I STP122G STP122GGalAhead™(FXI)ISTP122G(DVT) STP705STP707STP122G 管理層討論與分析 STP125GC3(ApoC3)INDINDI STP144GB(CFB) STP136G(AGT) STP237GAGTApoC3 STP247GCFB5(C5) PNP PNP—siRNAPNPRNA GalAhead™ GalAhead™RNAiRNAmRNAmxRNA™RNAimuRNA™RNAiASGPRsiRNA 管理層討論與分析 AODC SirnaomicsAODCJournal of Oncology Research and TherapyAODCRNAi SirnaomicsRNA 2024SirnaomicsGMPPNP CDMO(API)(PPQ) GalAhead™CDMO 2021PNP 2024 2024SirnaomicsSTP705STP122G 管理層討論與分析 STP705 isSCCSTP70569isSCCIIaIIb30BCCIIFDAFDAII/III BCCBCCII2023AESAE STP705ISTP70520249SirnaomicsJournal of Cosmetic DermatologysiRNA STP707 STP707I2023850STP707STP707SD20246SirnaomicsSTP707 I STP122G STP122GI12STP122G20247SirnaomicsGalNAcRNAiSTP122GI STP125GSTP144G20252026STP125GSTP144GINDCMCIND20247SirnaomicsApoC3STP125GIND 管理層討論與分析 20212024GalAhead™GMP EDIRNA 2024SirnaomicsRNAEDIRNASirnaomics 2024Sirnaomics9028 PNPPNP414PNPsiRNA24PNPsiRNALANPPNP-lipid20(PCT)153PNP 2024GalAhead™ RNAiGalAhead™20202418PCT (AODC)3 20242025Sirnaomics 管理層討論與分析 202412Sirnaomics 2024115Sirnaomics 2025SirnaomicsRNAiSirnaomics SirnaomicsRNARNAi Sirnaomics 管理層討論與分析 GalAhead™STP122GGalAhead™GalAhead™STP122G2025STP125G(IND) PNPSTP705FDAIIISTP705 STP705IFDAII STP707IIISTP707(CCA)(HCC)STP707(IV) 管理層討論與分析 STP705STP707GalAhead™ STP7052027NDAFDASTP705 SirnaomicsRNAi 管理層討論與分析 202412311.82024123150.22023123185.0 20241231 (i)(ii) 202412311.0202312311.40.429%202312311.02024123156,000202312310.4202412310.9 (i)(ii) 2024123120,000202312311.91.999%202312312.12024123144,000 管理層討論與分析 20241231202312310.218.2—— RNAimmuneRNAimmuneA 20241231202312311.56.9RNAimmune 202412311.90.3 (i)(ii) 202412312023123123.26.026%17.2 管理層討論與分析 (i)(ii)CRO(iii)(iv)(v)(vi)CRO 202412312023123154.433.662%20.8STP705STP122G20241231 管理層討論與分析 2024123116,00020231231170,00020231231150,000 (i)(ii) 20241231202312311.00.110%1.1 20241231 2023123185.02024123150.2(i)(ii)(iii)(iv)20241231 管理層討論與分析 2023123170.350.672%2024123119.7 202312315.4202412312.1(i)20241231(ii) 202312315.6202412315.820241231 20241231202412310.4 20241231 202412312023123123.911.8 2024123119.511.87.72024123137.211.60.40.70.223.70.6 202412312023123124.516.0(i)2024123118.2(ii)2023123123.92024123111.8 1.2. 202220231231155 202212292023112 202478202475 2024729(i)(ii) 管理層討論與分析 2024815202463020246301,935,000 2024111120248231,865,00070,000 2024123118,178,000 20241231202320.0 20251142025318 20241231 20241231 20241231 管理層討論與分析 20241231 12316920241231 2024123112.92.72023123123.33.6 董事及高級管理人員 46202410152024115 1920184202442023120241120231202410(i)201762017112012920176600267(ii)20071220128Sigma-Aldrich Fine ChemicalsMerck KGaAMRK 20015200512201012 2024123117,527,69616.67% 董事及高級管理人員 67 40202062024730014220208202472020620231220241202522018820231268816320173201982007120165Program for Appropriate Technology in Health(PATH)199972006101982119996International Journal of Biologicals 20004(CEIBS)199211982119779 70 00030 董事及高級管理人員 (i)20215CR-CP Life Science Fund Ma